Recent Analysts’ Ratings Updates for CVS Health (CVS)

CVS Health (NYSE: CVS) recently received a number of ratings updates from brokerages and research firms:

  • 4/21/2019 – CVS Health had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $80.00 price target on the stock.
  • 4/18/2019 – CVS Health had its price target lowered by analysts at Raymond James from $90.00 to $75.00. They now have a “strong-buy” rating on the stock.
  • 4/18/2019 – CVS Health is now covered by analysts at Guggenheim. They set a “buy” rating and a $75.00 price target on the stock.
  • 4/15/2019 – CVS Health had its “market perform” rating reaffirmed by analysts at CIBC.
  • 4/15/2019 – CVS Health was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
  • 4/11/2019 – CVS Health was given a new $73.00 price target on by analysts at Barclays PLC. They now have a “buy” rating on the stock.
  • 4/10/2019 – CVS Health is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $58.00 price target on the stock.
  • 4/10/2019 – CVS Health had its “buy” rating reaffirmed by analysts at Bank of America Corp. They now have a $74.00 price target on the stock, down previously from $82.00.
  • 4/10/2019 – CVS Health had its price target lowered by analysts at SunTrust Banks, Inc. from $85.00 to $65.00.
  • 3/12/2019 – CVS Health is now covered by analysts at Sanford C. Bernstein. They set an “outperform” rating and a $76.00 price target on the stock.
  • 3/6/2019 – CVS Health had its price target lowered by analysts at Citigroup Inc from $94.00 to $68.00. They now have a “buy” rating on the stock.
  • 2/28/2019 – CVS Health was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 2/25/2019 – CVS Health had its price target lowered by analysts at Argus from $100.00 to $80.00. They now have a “positive” rating on the stock.
  • 2/22/2019 – CVS Health was given a new $92.00 price target on by analysts at Morgan Stanley. They now have a “buy” rating on the stock.
  • 2/21/2019 – CVS Health had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $91.00 price target on the stock.
  • 2/21/2019 – CVS Health had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $80.00 price target on the stock.
  • 2/21/2019 – CVS Health had its price target lowered by analysts at Loop Capital to $68.00. They now have a “hold” rating on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 2/21/2019 – CVS Health had its price target lowered by analysts at SunTrust Banks, Inc. to $85.00. They now have a “buy” rating on the stock.
  • 2/21/2019 – CVS Health had its price target lowered by analysts at UBS Group AG from $75.00 to $74.00. They now have a “buy” rating on the stock.

Shares of CVS Health stock opened at $52.63 on Monday. The firm has a market cap of $68.34 billion, a PE ratio of 7.43, a P/E/G ratio of 1.03 and a beta of 0.94. The company has a current ratio of 1.03, a quick ratio of 0.65 and a debt-to-equity ratio of 1.22. CVS Health Corp has a 12-month low of $51.77 and a 12-month high of $82.15.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, February 20th. The pharmacy operator reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.07 by $0.07. The company had revenue of $54.42 billion for the quarter, compared to analyst estimates of $53.78 billion. CVS Health had a positive return on equity of 17.49% and a negative net margin of 0.31%. CVS Health’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.92 earnings per share. Equities research analysts predict that CVS Health Corp will post 6.79 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 3rd. Investors of record on Tuesday, April 23rd will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 3.80%. The ex-dividend date is Monday, April 22nd. CVS Health’s payout ratio is presently 28.25%.

In other news, COO Jonathan C. Roberts sold 77,639 shares of CVS Health stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $64.54, for a total transaction of $5,010,821.06. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David W. Dorman bought 9,600 shares of the business’s stock in a transaction dated Friday, March 8th. The shares were bought at an average cost of $52.71 per share, for a total transaction of $506,016.00. Following the purchase, the director now directly owns 122,302 shares in the company, valued at approximately $6,446,538.42. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 23,600 shares of company stock worth $1,270,896 and sold 245,671 shares worth $15,839,966. 0.53% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Bell Rock Capital LLC lifted its stake in shares of CVS Health by 764.0% in the fourth quarter. Bell Rock Capital LLC now owns 432 shares of the pharmacy operator’s stock worth $28,000 after buying an additional 382 shares in the last quarter. Daiwa SB Investments Ltd. purchased a new position in shares of CVS Health during the fourth quarter valued at approximately $30,000. Acima Private Wealth LLC purchased a new position in shares of CVS Health during the fourth quarter valued at approximately $33,000. Murphy Pohlad Asset Management LLC purchased a new position in shares of CVS Health during the fourth quarter valued at approximately $39,000. Finally, Cornerstone Advisors Inc. raised its holdings in shares of CVS Health by 71.6% during the third quarter. Cornerstone Advisors Inc. now owns 508 shares of the pharmacy operator’s stock valued at $40,000 after purchasing an additional 212 shares during the last quarter. 81.55% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.

Featured Story: How to calculate compound interest

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.